CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 75% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
US English
62.95
1.98%
Market Trading Hours* (UTC) Opens on Thursday at 08:10

Mon - Thu: 08:10 - 00:00

Fri: 08:10 - 21:00

  • Summary
  • Historical Data
Trading сonditions
Spread 0.32
Long position overnight fee

Long position overnight funding adjustment


Margin. Your investment $1,000.00
Overnight funding adjustment -0.026235 %
Charges from full value of position ($-4.98)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
-0.026235%
Short position overnight fee

Short position overnight funding adjustment


Margin. Your investment $1,000.00
Overnight funding adjustment 0.004012 %
Charges from full value of position ($0.76)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
0.004012%
Overnight fee time 21:00 (UTC)
Min traded quantity 1
Currency USD
Margin 5%
Stock exchange United States of America
Commission on trade 0%

Key Stats
Prev. Close 64.22
Open 64.22
1-Year Change -18.5%
Day's Range 62.74 - 64.49
  • Last Week
  • Last Month
  • Last Year
  • Last two Years
  • Max
  • Daily
  • Weekly
  • Monthly
Date Close Change Change (%) Open High Low
Jun 18, 2024 62.95 -1.04 -1.63% 63.99 64.52 62.63
Jun 17, 2024 64.05 -0.97 -1.49% 65.02 65.20 63.95
Jun 14, 2024 64.95 2.44 3.90% 62.51 65.54 62.15
Jun 13, 2024 63.57 -0.11 -0.17% 63.68 64.10 63.35
Jun 12, 2024 63.96 -0.73 -1.13% 64.69 65.14 63.80
Jun 11, 2024 64.75 -0.26 -0.40% 65.01 65.05 64.00
Jun 10, 2024 64.97 0.46 0.71% 64.51 65.22 63.79
Jun 7, 2024 64.47 0.81 1.27% 63.66 64.86 62.95
Jun 6, 2024 63.75 -0.08 -0.13% 63.83 64.23 62.97
Jun 5, 2024 63.77 -0.14 -0.22% 63.91 64.24 63.26
Jun 4, 2024 63.70 0.49 0.78% 63.21 64.55 62.83
Jun 3, 2024 63.27 -0.92 -1.43% 64.19 64.83 62.67
May 31, 2024 63.55 1.36 2.19% 62.19 64.24 61.95
May 30, 2024 61.91 -1.08 -1.71% 62.99 64.28 61.37
May 29, 2024 63.30 -0.41 -0.64% 63.71 63.84 63.05
May 28, 2024 63.90 -1.45 -2.22% 65.35 65.63 63.66
May 24, 2024 65.57 -0.55 -0.83% 66.12 66.42 65.16
May 23, 2024 66.12 -1.51 -2.23% 67.63 67.63 65.96
May 22, 2024 67.17 0.41 0.61% 66.76 67.83 66.59
May 21, 2024 67.21 -0.44 -0.65% 67.65 68.13 66.79

Trading calculator

Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

Trade commission
0
  • 1:1
Leverage
1:1
  • 20
  • 100
  • 500
  • 1000
  • 10000
Investment
Trade size (Leverage x Investement):
Open

Close

Short Long

For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

Gilead Company profile

What is Gilead Sciences?

Gilead Sciences Inc. is a US biopharmaceutical company. Following a series of mergers and acquisitions, Gilead is now one of the biggest players in its field with almost 9,000 employees working all over the globe. A portfolio of shipped products includes medicals for HIV treatment and HIV prevention. Gilead focuses on medical products that serve to cure oncology, liver diseases, cardiovascular disorders and many other severe health conditions. Gilead has a wide network of partnerships and collaborations.
 

What does the company do?

A research-based biopharmaceutical company, Gilead Sciences, discovers, produces and markets innovative healthcare products that are capable of transforming and simplifying medical care for people, who suffer from life-threatening diseases globally.

The portfolio of Gilead’s products and investigational drugs includes innovative treatments for AIDS/HIV, cancer, respiratory, inflammatory, liver diseases and cardiovascular conditions.
 

A bit of Gilead Sciences’ history

Gilead Sciences was established in June 1987. The company primarily focused on antiviral medicines. It concentrated on gene therapy, estimating the potential of genetic code blockers. The development and research of small molecule antiviral therapeutics started in 1991 with licensing of a group of nucleotide compounds (tenofovir was one of them) that further became widely-used anti-retroviral medicines. In 1990, Gilead collaborated with Glaxo for the development and research of genetic code blockers, known as antisense.

 

Who founded Gilead Sciences?

Gilead Sciences was founded by Michael L. Riordan, a 29-year-old doctor, who graduated from the Johns Hopkins School of Medicine, Washington University of St. Louis and the Harvard Business School. Riordan worked as the company’s CEO from its inception till 1996.

 

Establishing the company and its vision, Michael L. Riordan collaborated with three major scientific advisors, including Doug Melton of Harvard, Peter Dervan of Caltech and Harold Weintraub of the Fred Hutchinson Cancer Research Center.
 
A venture capital firm Menlo Ventures, where Riordan worked for one year, made the first investment of $2 million into Gilead Sciences.
 

Current size, team and locations

Headquartered in Foster City, California, US, the company operates across 6 continents and has a team of almost 9,000 employees. Gilead has a portfolio of 24 marketed products and is rapidly expanding. The research and development division works on over 400 clinical studies, evaluating compounds that potentially will become the next generation of efficient medicines.

 

Quick facts about Gilead Sciences

  • Developing access programmes to provide HIV and viral hepatitis medicines at significantly reduced prices in 134 low- and middle-income countries, the company serves approximately 10 million people in the developing world with Gilead’s HIV/AIDS therapies.
  • It is said that Riordan wanted to attract Warren Buffett as Gilead’s board member and investor, but was unsuccessful.
  • In 2005 the company created the Gilead Foundation, a non-profit organisation that is trying to improve the well-being and health of underserved communities in the United States and globally.
  • In 2016 the company gained $30.4 billion in revenue and was ranked the second in the Barron’s 500 rankings. The company also became the first in Business Insider’s list of top companies to work for.

How to learn the Gilead Sciences share price?

Gilead Sciences shares are listed and traded on the NASDAQ stock exchange under the ticker symbol GILD. The company is a component of the NASDAQ-100, S&P 500 and S&P 100 indices. Join Capital.com to trade CFDs on the Gilead Sciences share price fluctuations and follow the GILD chart in real-time.

Industry: Pharmaceuticals (NEC)

333 Lakeside Dr
FOSTER CITY
CALIFORNIA 94404-1147
US

News

Bank of England preview: no rate cut just yet despite CPI returning to 2%

The Bank of England (BoE) is widely expected to keep rates unchanged when it meets on Thursday. Analyst Daniela Harthorn looks at what this could mean

12:45, 18 June 2024

RBA Meeting Preview: No change to policy expected, markets look for fresh guidance

The Reserve Bank of Australia is expected to keep interest rates unchanged at 4.35% when it meets on Tuesday, June 18th, 2024, at 2:30 PM (AEST).

13:17, 17 June 2024

FOMC Decision Review: Rates unchanged as central bank raises inflation and interest rate forecasts

The FOMC left Federal Funds Rate unchanged at a target range of 5.25 to 5.50%.

10:55, 17 June 2024

Bank of Japan Preview: Markets look for guidance from BOJ about timing of next hike

The Bank of Japan meets on Friday, 14th of June, 2024. We preview what to expect from the BOJ decision and how it might impact the USD/JPY and Nikkei 225.

11:05, 12 June 2024

FOMC preview: Still expecting three rate cuts in 2024?

The Federal Reserve is expected to keep its policy unchanged on Wednesday – data from Reuters shows a 99% chance of no change. Last week’s 25-basis-point rate cut from the ECB has done nothing to change market expectations, and why should it?

08:20, 11 June 2024

US Non-Farm Payrolls Preview: Forecasts point to a stable labour market

US labour market conditions are expected to have remained stable in May. The latest Non-Farm Payrolls data will be released on Friday, June 7th, 2024, and will provide a health check on the US jobs market.

10:09, 5 June 2024

AUD/USD analysis: Focus turns to GDP data after unexpected CPI rise

Higher-than-expected monthly CPI data watered down expectations for RBA interest rate cuts in 2024; the markets will now shift attention to quarterly GDP data on Wednesday, June 5.

15:57, 4 June 2024

People also watch

ETH/USD

3,550.80 Price
-0.070% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 21:00 (UTC)
Spread 6.00

BTC/USD

65,151.10 Price
+0.400% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 21:00 (UTC)
Spread 106.00

XRP/USD

0.50 Price
-0.170% 1D Chg, %
Long position overnight fee -0.0753%
Short position overnight fee 0.0069%
Overnight fee time 21:00 (UTC)
Spread 0.01168

Gold

2,335.88 Price
+0.250% 1D Chg, %
Long position overnight fee -0.0191%
Short position overnight fee 0.0109%
Overnight fee time 21:00 (UTC)
Spread 0.40

Still looking for a broker you can trust?

Join the 620,000+ traders worldwide that chose to trade with Capital.com

1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading